Caladrius Biosciences, Inc. CLBS
0.43 0.00 (+0.00%)
At closeSep 15, 2022, 12:00 AM EDT
0.382 Day range 0.6497
52-week range unavailable
Analyst view
Consensus: buy
Buy
Price target (mean) 4.50 +955.3% upside
Now 0.4264
- Target (low)
- 3.00
- Target (mean)
- 4.50
- Target (high)
- 6.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 2
- 1 month ago 3
- 2 months ago 3
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.12 | -0.12 – -0.12 | -0.12 | 0.0% | 0 | 0.0% | 1 |
| Next quarter | -0.12 | -0.12 – -0.12 | -0.11 | -9.1% | 0 | 0.0% | 1 |
| Current year | -0.42 | -0.42 – -0.42 | -0.50 | +16.0% | 0 | 0.0% | 1 |
| Next year | -0.36 | -0.37 – -0.35 | -0.42 | +14.3% | 4.00M | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 23, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 3, 2021 | Brookline Capital | Maintained | — | Buy |
| May 14, 2019 | WBB Securities | Initiated | — | Speculative Buy |
| Mar 23, 2018 | Chardan Capital | Maintained | Buy | Buy |
| Mar 7, 2018 | H.C. Wainwright | Maintained | Buy | Buy |
| Aug 23, 2016 | Chardan Capital | Initiated | — | Buy |
| Apr 29, 2016 | H.C. Wainwright | Upgrade | Neutral | Buy |
| Jan 8, 2016 | Benchmark | Maintained | — | Hold |
| Jan 8, 2016 | H.C. Wainwright | Downgrade | Buy | Neutral |
| Jan 7, 2016 | Maxim Group | Downgrade | Buy | Hold |
| Aug 7, 2015 | Benchmark | Downgrade | Speculative Buy | — |